{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:43:11Z","timestamp":1792856591687,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1218,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1124\/jpet.120.000483","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T18:15:32Z","timestamp":1625163332000},"page":"207-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Monkeys and Translational Modeling for Selection of Dose and Frequency in Clinical Trials"],"prefix":"10.1016","volume":"378","author":[{"given":"Mitalee","family":"Tamhane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth T","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayssa","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000483_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1124\/dmd.30.4.421","article-title":"Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes","volume":"30","author":"Acheampong","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000483_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"10.1124\/jpet.120.000483_bib3","first-page":"920","article-title":"Production and drainage of aqueous humor in the cynomolgus monkey (Macaca irus)","volume":"4","author":"Bill","year":"1965","journal-title":"Invest Ophthalmol"},{"key":"10.1124\/jpet.120.000483_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1124\/jpet.120.000483_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data","volume":"137","author":"Del Amo","year":"2015","journal-title":"Exp Eye Res"},{"key":"10.1124\/jpet.120.000483_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0022-3565(24)29683-X","article-title":"Alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia","volume":"296","author":"Donello","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000483_bib8","first-page":"58","article-title":"Blood flow in the normal human retina","volume":"30","author":"Feke","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00417-005-1160-7","article-title":"Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization","volume":"243","author":"Ferencz","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1124\/jpet.120.000483_bib10","doi-asserted-by":"crossref","first-page":"e0161862","DOI":"10.1371\/journal.pone.0161862","article-title":"Neuroprotection by \u03b12-adrenergic receptor stimulation after excitotoxic retinal injury: a study of the total population of retinal ganglion cells and their distribution in the chicken retina","volume":"11","author":"Galindo-Romero","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000483_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.exer.2008.02.008","article-title":"Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments","volume":"86","author":"Hern\u00e1ndez","year":"2008","journal-title":"Exp Eye Res"},{"key":"10.1124\/jpet.120.000483_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/02713688108999452","article-title":"Ocular biometry of the cynomolgus monkey","volume":"1","author":"Kaufman","year":"1981","journal-title":"Curr Eye Res"},{"key":"10.1124\/jpet.120.000483_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0161-6420(00)00654-0","article-title":"Vitreous concentration of topically applied brimonidine tartrate 0.2%","volume":"108","author":"Kent","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.120.000483_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study","volume":"151","author":"Krupin","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.120.000483_bib16","doi-asserted-by":"crossref","unstructured":"Kuppermann BD, Patel SS, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, Guo Q, Schneider S and Lopez FJ (2020) Phase 2 study of the safety and efficacy of Brimonidine Drug Delivery System (Brimo DDS) Generation 1 in patients with geographic atrophy secondary to age-related macular degeneration. Retina. E-pub March 3.","DOI":"10.1097\/IAE.0000000000002789"},{"key":"10.1124\/jpet.120.000483_bib17","first-page":"2074","article-title":"Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death","volume":"42","author":"Lafuente","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S0952523802191152","article-title":"Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat","volume":"19","author":"Lai","year":"2002","journal-title":"Vis Neurosci"},{"key":"10.1124\/jpet.120.000483_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/jop.2007.0022","article-title":"A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies","volume":"24","author":"Merin","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/jpet.120.000483_bib20","first-page":"724","article-title":"The efficacy of topical administration of brimonidine to reduce ischaemia in the very early stage of diabetic retinopathy in good controlled type-2 diabetes mellitus","volume":"102","author":"Mondal","year":"2004","journal-title":"J Indian Med Assoc"},{"key":"10.1124\/jpet.120.000483_bib21","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1167\/iovs.15-17279","article-title":"Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized Macaque eyes","volume":"56","author":"Niwa","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2008.297","article-title":"Ophthalmic drug delivery: development and regulatory considerations","volume":"85","author":"Novack","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.120.000483_bib23","doi-asserted-by":"crossref","first-page":"e113798","DOI":"10.1371\/journal.pone.0113798","article-title":"A novel in vivo model of focal light emitting diode-induced cone-photoreceptor phototoxicity: neuroprotection afforded by brimonidine, BDNF, PEDF or bFGF","volume":"9","author":"Ort\u00edn-Mart\u00ednez","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000483_bib24","first-page":"1721","article-title":"Alpha2-adrenergic agonists selectively activate extracellular signal-regulated kinases in M\u00fcller cells in vivo","volume":"39","author":"Peng","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib25","first-page":"2993","article-title":"Cyto-\/neuro-protective effect of brimonidine drug delivery system (DDS) in a nonhuman primate progressive retinal degeneration model of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)","volume":"60","author":"Rajagopalan","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2015.0083","article-title":"Brimonidine can prevent in vitro hydroquinone damage on retinal pigment epithelium cells and retinal M\u00fcller cells","volume":"32","author":"Ram\u00edrez","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/jpet.120.000483_bib27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","article-title":"Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review","volume":"127","author":"Saylor","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1124\/jpet.120.000483_bib28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1167\/iovs.13-13650","article-title":"Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown","volume":"55","author":"Shen","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/02713683.2016.1238941","article-title":"The relationship of brimonidine concentration in vitreous body to the free concentration in retina\/choroid following topical administration in pigmented rabbits","volume":"42","author":"Shinno","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1124\/jpet.120.000483_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0192623307310955","article-title":"Safety evaluation of ocular drug delivery formulations: techniques and practical considerations","volume":"36","author":"Short","year":"2008","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.120.000483_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2337\/db18-0682","article-title":"Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy: Results of the EUROCONDOR clinical trial","volume":"68","author":"Sim\u00f3","year":"2019","journal-title":"Diabetes"},{"key":"10.1124\/jpet.120.000483_bib32","series-title":"Comparison of ocular tissue weights (volumes) and tissue collection techniques in commonly used preclinical animal species","author":"Struble","year":"2014"},{"key":"10.1124\/jpet.120.000483_bib43","first-page":"2154","article-title":"Ocular pharmacokinetics of brimonidine drug delivery system in rabbits and monkeys and its application in selecting dosing frequency in human clinical trials","volume":"57","author":"Tamhane","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib33","first-page":"1015","article-title":"The effect of melanin binding on brimonidine disposition in rabbit eyes","volume":"33","author":"Tang-Liu","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1167\/tvst.8.6.36","article-title":"Topical brimonidine or intravitreal BDNF, CNTF, or bFGF protect cones against phototoxicity","volume":"8","author":"Valiente-Soriano","year":"2019","journal-title":"Transl Vis Sci Technol"},{"key":"10.1124\/jpet.120.000483_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics"},{"issue":"Suppl 3","key":"10.1124\/jpet.120.000483_bib36","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0039-6257(01)00205-3","article-title":"Retinal ganglion cell death induced by retinal ischemia. Neuroprotective effects of two alpha-2 agonists","volume":"45","author":"Vidal-Sanz","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"10.1124\/jpet.120.000483_bib37","series-title":"Assessing Ocular Toxicology in Laboratory Animals","author":"Weir","year":"2013"},{"issue":"Suppl 1","key":"10.1124\/jpet.120.000483_bib38","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0039-6257(03)00004-3","article-title":"Role of alpha-2 agonists in neuroprotection","volume":"48","author":"Wheeler","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"10.1124\/jpet.120.000483_bib39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00417-005-0102-8","article-title":"Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial","volume":"244","author":"Wilhelm","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1124\/jpet.120.000483_bib40","first-page":"2849","article-title":"Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension","volume":"42","author":"WoldeMussie","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.120.000483_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1017\/S0952523807070605","article-title":"Localization of alpha 2 receptors in ocular tissues","volume":"24","author":"Woldemussie","year":"2007","journal-title":"Vis Neurosci"},{"key":"10.1124\/jpet.120.000483_bib42","first-page":"65","article-title":"Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration","volume":"40","author":"Yoles","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:53:04Z","timestamp":1739973184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0022356524257062"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000483","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Monkeys and Translational Modeling for Selection of Dose and Frequency in Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}